联系方式：400-650-8506
CNEN
产品名称 BI 6727 - Volasertib
产品货号 Axon 1473 CAS [755038-65-4] MF C34H50N8O3MW 618.81 Purity: 99% Optical purity: Optically pure Moderately soluble in DMSO Description A highly potent and selective polo-like kinase (PLK) 1 inhibitor (enzyme IC50 = 0.87 nM, EC50 = 11-37 nM on a panel of cancer cell lines), which exhibited significant anti-proliferative in multiple cancer models, including a model of taxane-resistant colorectal cancer. A high volume of distribution, indicating good tissue penetration, and a long terminal half-life have emerged as distinct features of BI 6727, which may have a favorable effect on antitumor efficacy in vivo. References Certificates Categories Extra info D Rudolph et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 2009, 15(9), 3094-3102.    P Schöffski. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009, 14(6), 559-570.  Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology EC 2.7.11.21 PLK PLK1 Inhibitor Chemical name N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide Parent CAS No. [755038-65-4] Order Size Unit Price Stock 2 mg €90.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

BI 6727 - Volasertib

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 1473

CAS [755038-65-4]

MF C34H50N8O3
MW 618.81

  • Purity: 99%
  • Optical purity: Optically pure
  • Moderately soluble in DMSO

BI 6727

Description

A highly potent and selective polo-like kinase (PLK) 1 inhibitor (enzyme IC50 = 0.87 nM, EC50 = 11-37 nM on a panel of cancer cell lines), which exhibited significant anti-proliferative in multiple cancer models, including a model of taxane-resistant colorectal cancer. A high volume of distribution, indicating good tissue penetration, and a long terminal half-life have emerged as distinct features of BI 6727, which may have a favorable effect on antitumor efficacy in vivo.
产品资料